Morphine Interaction with Aspirin: a Double-Blind, Crossover Trial in Healthy Volunteers

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 365; no. 2; pp. 430 - 436
• Main Authors: Bartko, Johann, Schoergenhofer, Christian, Schwameis, Michael, Wadowski, Patricia, Kubica, Jacek, Jilma, Bernd, Hobl, Eva-Luise
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2018
• Subjects: Adult; Aspirin - pharmacokinetics; Aspirin - pharmacology; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Morphine - pharmacology; Tissue Distribution - drug effects; AA; CT; NSTE-ACS; CEPI; PD; tmax; MEA; CEPI-CTs; PK; SA; ASA; AUC
• ISSN: 0022-3565; 1521-0103; 1521-0103
• DOI: 10.1124/jpet.117.247213

Aspirin is a cornerstone in the antiplatelet therapy for acute coronary syndromes. Coadministration of morphine may potentially influence the intestinal absorption, pharmacokinetics, and pharmacodynamics, as seen with P2Y12 inhibitors. In this trial, healthy volunteers were randomized to receive morphine (5 mg, i.v. bolus injection) at one of seven different time points before, after, or with aspirin (162 mg, p.o.) in a double-blind, placebo-controlled fashion. After a 14-day washout, subjects received placebo instead of morphine. Pharmacokinetics were determined by liquid chromatography, and aspirin’s effects were measured by platelet function tests (whole-blood platelet aggregation: multiplate, platelet plug formation: PFA-100). Morphine increased the total acetylsalicylic acid exposure by 20% compared with placebo when given simultaneously with aspirin, whereas Cmax and tmax were not altered. Morphine had no significant effect on aspirin-induced platelet inhibition. In contrast to coadministration with P2Y12 inhibitors, morphine appears to have negligible interaction with aspirin.